Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−262.5716USD
−252.85 MUSD
117.63 MUSD
1.23 M
About Acorda Therapeutics, Inc.
Sector
CEO
Ronald Cohen
Headquarters
New York
Website
Employees (FY)
102
Founded
1995
FIGI
BBG000FD2CZ7
Acorda Therapeutics, Inc. is a biopharmaceutical company that focuses on developing therapies that restore function and improve the lives of people with neurological disorders. Its products include Inbrija (levodopa inhalation powder), Ampyra (dalfampridine), and Fampyra (fampridine). The firm also offers Research and Development Programs like ARCUS for acute migraine, Cimaglermin alfa, and rHIgM22. The company was founded by Ronald Cohen in 1995 and is headquartered in New York, NY.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of ACORQ is 0.2450 USD — it has decreased by 2.00% in the past 24 hours. Watch Acorda Therapeutics, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on OTC exchange Acorda Therapeutics, Inc. stocks are traded under the ticker ACORQ.
ACORQ stock has fallen by 20.97% compared to the previous week, the month change is a 59.17% fall, over the last year Acorda Therapeutics, Inc. has showed a 97.85% decrease.
ACORQ reached its all-time high on Jan 13, 2015 with the price of 654480.0000 USD, and its all-time low was 0.2300 USD and was reached on Jun 14, 2024. View more price dynamics on ACORQ chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
ACORQ stock is 2.04% volatile and has beta coefficient of 3.24. Track Acorda Therapeutics, Inc. stock price on the chart and check out the list of the most volatile stocks — is Acorda Therapeutics, Inc. there?
Today Acorda Therapeutics, Inc. has the market capitalization of 304.31 K, it has decreased by 14.00% over the last week.
Yes, you can track Acorda Therapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
Acorda Therapeutics, Inc. is going to release the next earnings report on Aug 1, 2024. Keep track of upcoming events with our Earnings Calendar.
ACORQ net income for the last quarter is −27.40 M USD, while the quarter before that showed −217.76 M USD of net income which accounts for 87.42% change. Track more Acorda Therapeutics, Inc. financial stats to get the full picture.
No, ACORQ doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Jun 18, 2024, the company has 102.00 employees. See our rating of the largest employees — is Acorda Therapeutics, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Acorda Therapeutics, Inc. EBITDA is 551.00 K USD, and current EBITDA margin is 7.14%. See more stats in Acorda Therapeutics, Inc. financial statements.
Like other stocks, ACORQ shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Acorda Therapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Acorda Therapeutics, Inc. technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Acorda Therapeutics, Inc. stock shows the sell signal. See more of Acorda Therapeutics, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.